Ripac-Labor – Experience and commitment
The Ripac-Labor is a pioneer in its field: in 2002 we started to produce autogenous vaccines. In 2005 we were one of the first private veterinary laboratories in Germany to identify pathogens using MALDI-TOF mass spectrometry (MS). In order to continuously improve our products and services, we collaborate internationally with experts in our research projects.
Over the past years, we have trained our eye, refined our procedures, and established an extensive strain collection. With each new bacterial pathogen identified, our MALDI-TOF MS database grows and provides valid results for infection diagnostics. In order to improve not only our vaccines, but also to meet the growing demands and requirements for their production, we are implementing a GMP-compliant quality management system. It fills us with pride to be able to build a new and state-of-the-art production facility for this purpose.

Ripac-Labor GmbH – Data and Facts
- RI-PA-C: Riemerellae, Pasteurellae, Clostridiae and Coli bacteria
- A broad-based team of veterinarians, biologists, biochemists, agricultural engineers, VMTA, TMFA, MTA and BTA, among others.
- Expanding business with more than 40 employees
- Over 45,000 bacterial isolates in the master collection
- 2002: Foundation of Ripac-Labor GmbH
- 2005: Introduction of MALDI-TOF mass spectrometry for veterinary diagnostics
- 2007: Establishment in the Potsdam Science Park
- 2017: Dopharma International B.V. as majority shareholder
- 2020: Launch of the brand Dophavacc®
- 2021: Subsidiary of Dopharma International B.V.
- 2025: Official start of new build project